Introduction
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that has transformed the management of severe aortic stenosis, especially in patients at high surgical risk. However, thromboembolic events, including ischemic stroke, remain significant concerns following the procedure. Antiplatelet therapy is a cornerstone for reducing thrombotic risks after TAVR. Current guidelines often recommend single antiplatelet therapy (SAPT) or double antiplatelet therapy (DAPT), but their comparative effects on long-term ischemic stroke risks, particularly disabling strokes, remain under investigation.
This article examines the impact of SAPT and DAPT on the risk of disabling ischemic stroke within 6–12 months post-TAVR, drawing on recent studies and clinical data.
Pathophysiology and the Role of Antiplatelet Therapy
Thromboembolic complications after TAVR are influenced by factors such as procedural techniques, device implantation, and patient comorbidities, including atrial fibrillation. SAPT typically involves aspirin, while DAPT combines aspirin with a P2Y12 inhibitor like clopidogrel. Both regimens aim to mitigate platelet aggregation and thrombus formation, yet they carry differing risks for bleeding and ischemic events.
Single Antiplatelet Therapy (SAPT)
SAPT is increasingly favored due to its lower bleeding risk compared to DAPT. Clinical studies suggest SAPT provides sufficient protection against ischemic events in most patients, especially those without atrial fibrillation or other high-risk conditions.
Key findings include:
Stroke Risk: SAPT demonstrates comparable efficacy to DAPT in preventing ischemic stroke within 6–12 months post-TAVR in low-risk populations.
Bleeding Complications: SAPT significantly reduces major bleeding complications, enhancing overall safety.
For example, the recent ARTE trial highlighted no substantial difference in disabling stroke rates between SAPT and DAPT, while SAPT significantly reduced bleeding events.
Double Antiplatelet Therapy (DAPT)
DAPT was traditionally recommended to provide broader protection against thrombotic events. However, emerging evidence questions its superiority over SAPT, particularly in balancing ischemic and bleeding risks.
Key findings include:
Stroke Risk: DAPT may provide marginal additional protection against thrombotic events in patients with specific risk factors (e.g., atrial fibrillation, prior strokes).
Bleeding Risk: The addition of a P2Y12 inhibitor significantly increases the risk of major and life-threatening bleeding, which can offset its benefits.
Studies like POPular-TAVI have shown that DAPT does not significantly reduce disabling ischemic stroke rates compared to SAPT and increases the risk of bleeding complications, leading to a shift in guideline recommendations.
Comparative Outcomes on Disabling Ischemic Stroke
Disabling ischemic stroke, characterized by profound neurological deficits, significantly impacts post-TAVR quality of life. Data suggest:
Within the 6–12-month period post-TAVR, SAPT and DAPT offer similar protection against disabling ischemic strokes in most patients.
The bleeding risks associated with DAPT often outweigh its marginal benefits in reducing stroke risks, particularly for disabling strokes.
A meta-analysis of randomized controlled trials revealed no statistically significant difference in disabling stroke incidence between SAPT and DAPT groups, underscoring the growing preference for SAPT in standard-risk patients.
Clinical Implications and Recommendations
The choice between SAPT and DAPT should be individualized based on patient risk profiles:
Low-risk patients: SAPT is preferred due to its comparable efficacy and reduced bleeding risks.
High-risk patients (e.g., atrial fibrillation, prior thromboembolism): Anticoagulation or a carefully monitored DAPT regimen may be necessary.
Emerging evidence supports simplifying antithrombotic therapy post-TAVR to minimize adverse events, aligning with recent guideline updates advocating for SAPT in the majority of patients.
Conclusion
SAPT and DAPT exhibit similar efficacy in preventing disabling ischemic stroke within 6–12 months post-TAVR, but SAPT offers a superior safety profile by reducing major bleeding risks. Tailoring antiplatelet therapy to individual patient risks remains critical to optimizing outcomes after TAVR. As research evolves, ongoing trials will refine these strategies, further enhancing patient care.
